Cardiovascular Disease (CVD) News and Information

Telmisartan (Micardis®) as effective as ramipril but with better long-term tolerability in high-risk cardiovascular Asian patients

First landmark ARB trial against placebo shows Micardis® (telmisartan) reduces the risk of cardiovascular death, heart attack and stroke in ACE-intolerant high-risk patients

Landmark trial ONTARGET proves telmisartan is as protective as ramipril and better tolerated in a broad high-risk cardiovascular population.
From ONTARGET® it may be concluded that telmisartan can prevent every 5th serious cardiovascular event.